The Children's Hospital of Philadelphia signed a preclinical research agreement with Lund, Sweden-based NeuroVive Pharmaceutical AB to advance research and development in models of mitochondrial complex I dysfunction.
The financial terms of the agreement were not disclosed.
"We feel fortunate to be able to initiate this collaboration with a well-recognized institution like CHOP…This is an important step in further advancing and strengthening our [mitochondrial research] program, as well as in the development of novel treatment opportunities for people with mitochondrial medicine disorders," said Magnus Hansson, CMO of NeuroVive.